Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyPEPI1018 Vaccine + TAS-102 in Late-Stage Metastatic Colorectal Cancer
NCT05130060Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PolyPEPI1018 in colorectal cancer (CRC), sponsored by Mayo Clinic. Primary endpoint: Incidence of adverse events up to 1 year. Started Jan 2022; status: completed.
02
Drugs
PolyPEPI1018
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05130060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130060.